Multiple Sclerosis Journal · 2018 · 81 citations · 21 references
Life SciencesNeurologyNeuroscienceClinical NeuroscienceNeurodegenerationNeuroimmunologyCerebrospinal Fluid BiomarkersDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeuroinflammationNeurologic PrognosticationClinical Outcome MeasurementDisability Status AnalysisDisability Status DeterminationLong-term Outcome PredictionNeurofilament Heavy ChainNeurofilament ProteinsPredictive Biomarker DevelopmentPredictive Biomarker Discovery
BACKGROUND: The role of biomarkers to predict clinical outcome in multiple sclerosis (MS) is still debated. OBJECTIVE: To test whether cerebrospinal fluid (CSF) light-chain neurofilament (NfL) levels in newly diagnosed patients with MS could predict clinical outcome over a 10-year period. METHODS: Patients with newly diagnosed MS underwent standardized clinical assessments at baseline and 5 and 10 years of follow-up. Expanded Disability Status Scale (EDSS) progression between assessments was defined as an increase in one point or more if <6 and 0.5 or more if ≥6. CSF obtained at baseline was analyzed for levels of NfL using enzyme-linked immunosorbent assay technology. RESULTS: A total of 44 patients were included. In all, 35 patients (80%) had relapsing-remitting multiple sclerosis (RRMS). Patients who progressed in EDSS showed a trend for higher median baseline CSF-NfL levels than patients who did not progress after 5 years (947 ng/L vs 246 ng/L, p = 0.05), and although not statistically significant, after 10 years (708 ng/L vs 265 ng/L, p = 0.28). Patients who converted from RRMS to secondary-progressive multiple sclerosis (SPMS) at 5 years had a statistical significant higher median CSF level of NfL (2122 ng/L vs 246 ng/L, p = 0.01). CONCLUSION: CSF levels of NfL at the time of diagnosis seems to be an early predictive biomarker of long-term clinical outcome and conversion from RRMS to SPMS.
21
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
Giulio Disanto, Christian Barro, Pascal Benkert et al. · Annals of Neurology · 2017 · 1.2K citations · Full text
Jens Kühle, Christian Barro, Ulf Andréasson et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2016 · 739 citations
Defining high, medium and low impact prognostic factors for developing multiple sclerosis
Mar Tintoré, Àlex Rovira, Jordi Río et al. · Brain · 2015 · 520 citations
Medicine, Biostatistics, Neurology +15
Long‐term evolution of multiple sclerosis disability in the treatment era
Bruce Cree, Pierre‐Antoine Gourraud, Carolyn Bevan et al. · Annals of Neurology · 2016 · 436 citations · Full text